Home＞ORGANIZATION
Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec(Dec.6.2016)
Japan should not make a hasty decision on the direction of its drug pricing reform without the pharmaceutical industry at the table, Jay Taylor, vice president of international affairs of the Pharmaceutical Research and Manufacturers of America (PhRMA), warned on December 2 ...
(LOG IN FOR FULL STORY)
-
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman Oct.16
-
Asian Consortium for Natural Substance-Based Drug Discovery to Leverage Asian Natural Resources, Japanese Technologies
Oct.15
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize Oct.03
- Generic Use Rate at 72.2% in April-June: JGA Oct.01
-
October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
Sep.25
- MHLW Lifts Contraindications for Combined Statin-Fibrate Use in Renal-Impaired Patients(Oct.17)
- Eisai Seals Latin America Pact for Belviq(Oct.17)
- Teva Takeda Launches Voluntary Recall for Taxotere Generics(Oct.17)
- ADR Victim Relief Claims Fall below 1,500 in FY2017: MHLW(Oct.17)
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman(Oct.16)
